4-O-Podophyllotoxin sulfamate derivatives were prepared using the natural lignan podophyllotoxin. The prepared compounds were afforded by reacting O-sulfonyl chloride podophyllotoxin with ammonia or aminoaryl/heteroaryl motif. Biological evaluation was performed in human breast cancer (MCF7), ovarian cancer (A2780), colon adenocarcinoma (HT29), and normal lung fibroblast (MRC5) cell lines. Compound 3 exhibited potent inhibitory activity and good selectivity margin. Compounds 2, 3, and 7 exerted apoptotic effect in MCF7 cells in a dose-dependent manner. The cytotoxicity of the verified compounds was inferior to that of podophyllotoxin.
Cancer remains the second leading cause of death worldwide, highlighting the urgent need for novel therapeutic agents. In this work, twenty derivatives of N-benzyl-6-chloro-4-hydroxy-2-quinolone-3-carboxamides were synthesized and spectroscopically analyzed using FT-IR, NMR (1H and 13C), and elemental analysis. Substitution of benzyl moiety with o-CH3 (8), p-OCH3 (10), m-CH3 (18), p-CH3 (19), and p-CF3 (21) demonstrated three-fold distinct cytotoxicity against human colon cancer (HCT-116) cells with IC50s of 72.0, 100.0–112.0 µM. The cheminformatics calculations disclosed that the analogues possess diverse physicochemical properties and invariable predictions across six drug-likeness scoring models, supporting their potential cytotoxicity profile against colorectal cancer cell lines (Caco-2 and HCT-116). The docking studies against both wild-type and mutant PI3Kα clarified binding interactions, implying that particular functionalities improve efficacy and selectivity. This study provides further evidence for the therapeutic promise of quinolones in targeting cancer-specific pathways and expedites the process for developing potent anticancer agents.
17 July 2026 in Bioorganic & Medicinal Chemistry Letters
Phosphatidylinositol 3-kinase alpha (PI3Kα) and cyclin-dependent kinase 7 (CDK7) play key roles in the growth of multiple cancers. PI3Kα indirectly activates and enhances CDK7 expression. Our preliminary findings from screening recombinant PI3Kα on the Kinome Array showed that it may directly activate CDK7 and presents promising targets for the development of novel drugs with dual inhibition. In this work, we designed and synthesized two hybrids, HY3 and HY5, employing the strategy of combining the cores of Alpelisib and SY-5609, known selective inhibitors of PI3Kα and CDK7, respectively. HY3 showed 98% inhibition against CDK7 and 10% against PI3Kα. 10-point titration of HY3 was determined against CDK7 with an IC50 = 10.8 nM. We then developed a potent hybrid inhibitor (HY5) employing X-ray structure-based drug design. HY5 showed dual inhibition, 87% inhibition with IC50 of 87.9 nM against PI3Kα and 89% inhibition with IC50 of 638 nM against CDK7. We also screened HY5 for cytotoxicity against HCT116, SKOV3 and MCF7 cells exhibiting IC50s of 360 nM, 490 nM, and 820 nM, respectively. To compare selective killing of cancer cells, we tested HY5 against several normal cell lines: human fibroblast (WI-38), retinal pigmented epithelial cells (RPE), mouse embryonic cell line (10T1/2), and canine kidney (MDCK). HY5 was significantly less toxic against WI-38 and showed similar toxicity against 10T1/2, RPE and MDCK cells at 5, 10 and 20 μM which is comparable to the Alpelisib + SY-5609 combination. HY5 showed high selectivity for MCF7 cells where 80% were killed at 1 μM compared to only 10-50% of norm5al cells at 20 μM.
14 October 2025 in ACS Medicinal Chemistry Letters